Loading
Loading
Healthcare
Executive compensation benchmarks for 54 public companies in the pharmaceutical preparations industry.
$13.1M
54
$246.0M
150:1
Median
$13,107,123
Average
$20,759,020
25th Percentile
$8,414,649
75th Percentile
$19,164,421
Minimum
$819,000
Maximum
$246,047,279
Avg Pay Ratio
150:1
Companies
54
Published peer groups
Compare the company-size groups with enough data to support a distinct benchmark.
Click any company to see full compensation breakdown
The median pharmaceutical preparations CEO compensation is $13,107,123, based on 54 public companies. The average is $20,759,020. Note that CEO compensation includes salary, bonus, stock awards, option awards, and other compensation.
Mahkam Zanganeh of Summit Therapeutics Inc. is the highest paid pharmaceutical preparations CEO, with total compensation of $246,047,279 in FY2025.
The average CEO-to-median-employee pay ratio in the pharmaceutical preparations industry is 150:1. This means the average CEO earns 150 times what the median employee earns.
Data sourced from SEC filings (DEF 14A proxy statements). Last updated: July 16, 2026. Compensation figures are total annual compensation including salary, bonus, stock awards, and other compensation.
Compare CEO compensation across different industries or research specific companies.
| Company | CEO | Total Comp |
|---|---|---|
| Summit Therapeutics Inc. SMMT | Mahkam Zanganeh | $246.0M |
| Roivant Sciences Ltd. ROIV | Matthew Gline | $163.3M |
| ELI LILLY & Co LLY | David A. Ricks | $36.7M |
| JOHNSON & JOHNSON JNJ | Joaquin Duato | $32.8M |
| AbbVie Inc. ABBV | Robert A. Michael | $32.5M |
| Cogent Biosciences, Inc. COGT | Andrew Robbins | $27.8M |
| ABBOTT LABORATORIES ABT | Robert B. Ford | $24.2M |
| ASTRAZENECA PLC AZN | Pascal Soriot | $23.8M |
| PTC THERAPEUTICS, INC. PTCT | Matthew B. Klein | $23.3M |
| BIOMARIN PHARMACEUTICAL INC BMRN | Alexander Hardy | $21.9M |
| VERTEX PHARMACEUTICALS INC / MA VRTX | Reshma Kewalramani | $21.1M |
| Merck & Co., Inc. MRK | Robert M. Davis | $20.8M |
| MADRIGAL PHARMACEUTICALS, INC. MDGL | Bill Sibold | $19.2M |
| TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA | Richard Francis | $19.2M |
| Jazz Pharmaceuticals plc JAZZ | Renee D. Gala | $19.2M |
| RHYTHM PHARMACEUTICALS, INC. RYTM | David P. Meeker | $17.5M |
| Organon & Co. OGN | Kevin Ali | $15.8M |
| SUPERNUS PHARMACEUTICALS, INC. SUPN | Jack A. Khattar | $15.5M |
| CORCEPT THERAPEUTICS INC CORT | Joseph K. Belanoff | $15.3M |
| Viatris Inc VTRS | Scott A. Smith | $15.3M |
| BridgeBio Pharma, Inc. BBIO | Neil Kumar | $14.9M |
| Alnylam Pharmaceuticals, Inc. ALNY | Yvonne L. Greenstreet | $14.9M |
| INSMED Inc INSM | William H. Lewis | $14.5M |
| UNITED THERAPEUTICS Corp UTHR | Michael Benkowitz | $14.4M |
| Avidity Biosciences, Inc. RNA | Sarah Boyce | $14.2M |
| IONIS PHARMACEUTICALS INC IONS | Brett P. Monia | $13.4M |
| Apellis Pharmaceuticals, Inc. APLS | Cedric Francois | $13.3M |
| Protagonist Therapeutics, Inc PTGX | Dinesh V. Patel | $12.9M |
| Acadia Pharmaceuticals Inc. ACAD | Stephen R. Davis | $12.2M |
| CYTOKINETICS INC CYTK | Robert I. Blum | $11.9M |
| Pacira BioSciences, Inc. PCRX | Frank Lee | $11.6M |
| LIGAND PHARMACEUTICALS INC LGND | Todd C. Davis | $11.5M |
| Nuvalent, Inc. NUVL | James R. Porter | $11.4M |
| Axsome Therapeutics, Inc. AXSM | Herriot Tabuteau | $10.3M |
| ANI PHARMACEUTICALS INC ANIP | Nikhil Lalwani | $10.3M |
| Merus N.V. MRUS | Sven (Bill) Ante Lundberg | $9.7M |
| Arcus Biosciences, Inc. RCUS | Terry Rosen | $9.7M |
| PERRIGO Co plc PRGO | Patrick Lockwood-Taylor | $9.0M |
| ARROWHEAD PHARMACEUTICALS, INC. ARWR | Christopher Anzalone | $9.0M |
| Amneal Pharmaceuticals, Inc. AMRX | Chintu Patel | $8.7M |
| Amphastar Pharmaceuticals, Inc. AMPH | Jack Yongfeng Zhang | $8.3M |
| Alkermes plc. ALKS | Richard F. Pops | $7.9M |
| Harmony Biosciences Holdings, Inc. HRMY | Jeffrey Dayno | $7.9M |
| Sarepta Therapeutics, Inc. SRPT | Douglas S. Ingram | $7.8M |
| REGENERON PHARMACEUTICALS, INC. REGN | Leonard S. Schleifer | $7.3M |
| BeOne Medicines Ltd. ONC | John V. Oyler | $5.6M |
| Xencor Inc XNCR | Bassil I. Dahiyat | $5.5M |
| Innoviva, Inc. INVA | Pavel Raifeld | $5.4M |
| PHIBRO ANIMAL HEALTH CORP PAHC | Jack C. Bendheim | $5.3M |
| Schrodinger, Inc. SDGR | Ramy Farid | $4.1M |
| Grifols, S.A. GRFS | Jose Ignacio Abia Buenache | $3.5M |
| COLLEGIUM PHARMACEUTICAL, INC COLL | Vikram Karnani | $1.7M |
| Royalty Pharma plc RPRX | Pablo Legorreta | $938K |
| KAMADA LTD KMDA | Amir London | $819K |